SCHEMBL3111012

SCHEMBL3111012

CCCCCCCCCC1OCC(CO)O1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 2/20 0.61
PRKCG P05129 2/20 0.61
PRKCB P05771 2/20 0.61
PRKCA P17252 2/20 0.61
PRKCH P24723 2/20 0.61
PRKCI P41743 2/20 0.61
PRKCE Q02156 2/20 0.61
PRKCQ Q04759 2/20 0.61
PRKCZ Q05513 2/20 0.61
PRKCD Q05655 2/20 0.61
PRKD1 Q15139 2/20 0.61
ALDH1A1 P00352 1/20 0.59
ENPP2 Q13822 13/20 0.55
LPAR2 Q9HBW0 8/20 0.55
EPHX1 P07099 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1681846 1.00 PRKD3 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL16638072 1.00 PRKD3 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL9873267 1.00 PRKD3 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL21518914 1.00 PRKD3 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL16912929 1.00 PRKD3 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL25268261 1.00 PRKD3 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL22960177 1.00 PRKD3 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL21518916 1.00 PRKD3 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL22960173 1.00 PRKD3 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL3785512 1.00 PRKD3 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179151-A1 TRANSDERMAL APPLICATION OF TRIAZINES FOR CONTROLLING INFECTIONS WITH COCCIDIA BAYER ANIMAL HEALTH GMBH (DE) 2010-07-15 US disclosed
US-7652071-B2 Penetration of active substances into cells and organs ALPHA-BIOCARE GMBH (DE) 2010-01-26 US disclosed
US-7652071-B2 Penetration of active substances into cells and organs ALPHA-BIOCARE GMBH (DE) 2010-01-26 US disclosed
CN-101505756-A Transdermal administration of triazines to control coccidial infections BAYER ANIMAL HEALTH GMBH (DE) 2009-08-12 CN disclosed
EP-2054064-A2 TRANSDERMAL APPLICATION OF TRIAZINES FOR CONTROLLING COCCIDIA INFECTIONS Bayer Animal Health GmbH (DE) 2009-05-06 EP disclosed
EP-1613354-B1 USE OF CYCLIC ACETALS/ CETALS FOR IMPROVED PENETRATION OF ACTIVE SUBSTANCES INTO CELLS AND ORGANS BAYER HEALTHCARE AG (DE) 2008-08-20 EP disclosed
WO-2008019785-A2 TRANSDERMAL APPLICATION OF TRIAZINES FOR CONTROLLING COCCIDIA INFECTIONS BAYER ANIMAL HEALTH GMBH (DE) 2008-02-21 WO disclosed
US-20070270503-A1 Penetration of Active Substances Into Cells and Organs BAYER HEALTHCARE AG (DE) 2007-11-22 US disclosed
US-20070270503-A1 Penetration of Active Substances Into Cells and Organs BAYER HEALTHCARE AG (DE) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179151-A1 TRANSDERMAL APPLICATION OF TRIAZINES FOR CONTROLLING INFECTIONS WITH COCCIDIA TTL, IL5, DPM1 PRKD3 3865/4885PRKCG 3628/4885PRKCB 3744/4885
US-20070270503-A1 Penetration of Active Substances Into Cells and Organs SLC2A1, SLC2A2, SLC2A3 PRKD3 2782/4885PRKCG 2184/4885PRKCB 2227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.